Roche says study shows its HIV drug Invirase as effective as Kaletra |
|
|
|
Published
:
Thu, 25 Oct 2007 07:09
|
ZURICH (Thomson Financial) - Roche Holdings AG said a phase IIIb trial indicates that its HIV drug Invirase is as effective as the commonly used protease inhibitor Kaletra on HIV patients.In addition, fewer patients given Invirase showed developed elevated triglyceride levels, which is associated with an increase in a person's risk of cardiovascular or cerebrovascular disease, said the Swiss pharma giant.The findings from the trial, involving 337 patients, showed that patients treated with Invirase had similar levels of viral suppression as those treated with Kaletra, which is manufactured by US company Abbott Laboratories.huimin.neo@thomson.comhmn/roCOPYRIGHTCopyright Thomson Financial News Limited 2007. All rights reserved.The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
|
|
|
|
Print this Story
BioXell to commence phase IIa trial on Elocalcitol's effects on male infertility 